Myoscint
Executive Summary
Centocor files PLA for the cardiac imaging agent March 31. Centocor said that clinical studies have been conducted in about 1,000 patients during the past three and one-half years. Potential indications include detection of post-heart attack cardiac damage, diagnosing myocarditus and diagnosing heart transplant rejection.